Darren P. Wallace

This study uses CRISPR activation to increase PKD1 expression in ADPKD models, reducing cyst formation and improving cellular features.

This study shows pirfenidone reduces fibrosis and improves kidney function in ADPKD by targeting myofibroblast activation and ECM production.

This study shows that autophagy in myofibroblasts drives cyst growth in ADPKD by promoting paracrine stimulation of epithelial cells, with lactate and HIF1 playing key roles.

This study shows that CILK1 accumulates in an inactive form during ADPKD progression in human and mouse models.

This study shows that apelin reduces cyst growth and improves kidney function in a mouse model of ADPKD by inhibiting cAMP synthesis and downregulating cyst-related genes.

This study shows that targeting Ogt in ADPKD reduces cyst formation and extends survival by normalizing metabolic pathways and preserving cellular energy production.

This study shows that inhibiting CYP2E1 with 4MP protects kidneys from cisplatin toxicity but does not affect cisplatin's anti-cancer effects in bladder cancer cells.

This study identifies cis-inhibition of PKD1 and PKD2 mRNAs via miR-17 in ADPKD and shows that disrupting this mechanism reduces cyst growth in multiple models.

This study shows that deleting the IFT-A gene Thm1 in ADPKD mouse models has development-specific effects on kidney cysts, inflammation, and cilia length, suggesting environmental factors influence ciliary homeostasis and disease progression.

This study shows Quinomycin A reduces cyst progression in PKD by inhibiting Notch signaling and normalizing cilia lengths in a mouse model and human cells.